LITTLE ROCK, Ark., Feb. 27 /PRNewswire/ -- Cauley Bowman Carney & Williams, PLLC announces an investigation into the proposed acquisition of CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI). On February 26, 2008, CollaGenex announced that it has entered into a definitive merger agreement with an affiliate of Galderma Pharma S.A. Under the terms of the proposal, CollaGenex's shareholders would receive $16.60 per share in cash for each share owned. This price per share represents an approximately 33% premium over the stock's closing price of $16.23 prior to announcement of the acquisition.
Cauley Bowman Carney & Williams, PLLC
Cauley Bowman is a national law firm that represents investors in securities fraud and corporate governance class actions. It is one of the country's premier firms in the area of securities fraud having recovered billions of dollars for defrauded investors and secured significant corporate governance reforms. Cauley Bowman maintains in-house finance, forensic accounting specialists and extensive trial experience.
If you are a current shareholder of CollaGenex Pharmaceuticals, Inc.
and would like to be advised of your rights in this matter, you may contact
Cauley Bowman Carney & Williams, PLLC at the phone number below.
Darrin L. Williams, Esq.
Randall K. Pulliam, Esq.
|SOURCE Cauley Bowman Carney & Williams, PLLC|
Copyright©2008 PR Newswire.
All rights reserved